Cytokinetics, Incorporated filings document a specialty cardiovascular biopharmaceutical company with common stock listed on the Nasdaq Global Select Market. Its 8-K reports cover financial results, corporate presentations, MYQORZO® regulatory approvals, clinical and regulatory disclosures, and material capital-structure events such as underwriting agreements for common stock offerings.
Proxy materials describe board elections, executive compensation, auditor ratification and equity plan amendments, including matters tied to the company’s employee stock purchase plan. Other filings address governance changes, risk disclosures, registered securities, exhibits and Inline XBRL cover-page data associated with Cytokinetics’ public-company reporting obligations.
Robert I. Blum, President & CEO and a director of Cytokinetics, Inc. (CYTK), reported a sale of 5,000 shares of the issuer's common stock on 09/02/2025 at a reported price of $48.76 per share. After the transaction, Mr. Blum is shown as beneficially owning 378,108 shares directly and additionally reports indirect beneficial ownership of 2,083 shares held by each of two irrevocable trusts (The Bridget Blum 2003 Irrevocable Trust and The Brittany Blum 2003 Irrevocable Trust). The Form 4 was signed by an attorney-in-fact for Mr. Blum.
Cytokinetics, Inc. (CYTK) Form 144 notice reports a proposed sale of 6,756 common shares through Morgan Stanley Smith Barney, with an aggregate market value of $238,689.48 based on the filing. The filing lists 119,657,156 shares outstanding and an approximate sale date of 09/02/2025. The shares to be sold were acquired as Restricted Stock Units on 01/03/2022 and payment is marked N/A. The filer also disclosed 10b5-1 sales by Edward Kaye of 3,636 shares on 06/05/2025 for $116,714.87. The document contains standard Rule 144 attestations and a signature block; no relationship to the issuer or additional context is provided in the filing.
Cytokinetics Inc. (CYTK) reports a non-derivative equity award to director James M. Daly. On 08/19/2025 Mr. Daly received a non-qualified stock option to purchase 27,450 shares of common stock with an exercise price of $37.84 per share. The option becomes exercisable on 09/19/2025 and expires on 08/19/2035. Following the reported transaction, Mr. Daly beneficially owns 27,450 shares underlying the option as a direct position. The filing states this was an initial grant to a new director.
CYTK Form 3 — initial statement by Director James M. Daly This filing reports that James M. Daly, listed as a director of Cytokinetics, Inc., filed an initial Form 3 dated 08/19/2025 and reports no securities beneficially owned in the issuer. The form was signed by an attorney-in-fact on Mr. Daly’s behalf.
Cytokinetics, Incorporated reported that its Board of Directors appointed James M. Daly as a Class III director effective August 19, 2025, with a term running through the company’s 2028 annual stockholders’ meeting. He will also serve on the Board’s Compliance Committee, and the Board has determined he is independent under SEC rules, Nasdaq standards and the company’s governance guidelines. The company states there are no related-party transactions requiring disclosure.
Mr. Daly will receive standard non-employee director compensation, including a $50,000 annual cash retainer for Board service and $7,500 annually for Compliance Committee service, both pro-rated for partial periods. He is also eligible for an annual equity award of restricted stock units and stock options with a combined grant date fair value of $440,000. In addition, on the effective date he received an initial stock option to purchase 27,450 shares, valued at $700,000, vesting monthly over three years, subject to continued Board service, and the company entered into its standard indemnification agreement with him.
Insider transactions by Dr. Malik Fady Ibraham, EVP Research & Development of Cytokinetics (CYTK), are reported on Form 4. On 08/19/2025 he exercised 2,000 non‑qualified stock options at an exercise price of $10.60 and concurrently sold 2,000 shares at $38.31. After these transactions he beneficially owned 140,610 shares. The filing shows 9,105 option shares remaining exercisable from the option series.
Insider transaction summary for CYTK: The Form 4 shows Robert I. Blum, President & CEO and a director of Cytokinetics Inc. (CYTK), reported a sale of 5,000 shares of the issuer's common stock on 08/15/2025 at a price of $38.42 per share. After the reported sale, Mr. Blum is recorded as directly owning 383,108 shares. The filing also discloses indirect holdings of 2,083 shares held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust.
The Form 4 was filed by one reporting person and indicates the transaction may have been made pursuant to a written plan under Rule 10b5-1. The filing is signed by an attorney-in-fact for Mr. Blum on 08/15/2025.
Cytokinetics (CYTK) Q2-25 10-Q highlights: Revenue jumped to $66.8 m (Q2-24: $0.3 m) and $68.3 m for H1, driven by the Bayer Japan license (one-time $52.4 m recognition) and two €5 m milestones. Collaboration revenue remains modest. Operating loss narrowed to $111.5 m (-14% YoY), but six-month operating loss widened to $335.5 m. Net loss was $134.4 m for the quarter (-$1.12/sh) and $295.7 m YTD.
Balance sheet & liquidity: Cash, cash equivalents and investments total $1.0 bn, down from $1.2 bn at FY-24. Quarterly cash burn from operations was $259.9 m. Total liabilities rose to $1.59 bn (incl. $554 m convertible notes and $489 m revenue-participation liabilities) producing a stockholders’ deficit of $368.7 m. Additional $75 m was drawn on Royalty Pharma Tranche 4 in April; Tranche 5 ($100 m) remains available through Nov-25.
Pipeline/regulatory: NDA for aficamten in obstructive HCM accepted; PDUFA target date 26 Dec 2025. Phase 3 programs in non-obstructive HCM and pediatric HCM progressing. Omecamtiv mecarbil Greater China license terminated; rights reverted to CYTK. Cash runway expected to cover at least 12 months; management anticipates continued losses until commercial launch.